S&P 500   4,235.52 (+0.14%)
DOW   32,976.90 (-0.08%)
QQQ   357.04 (+0.60%)
AAPL   172.33 (-0.04%)
MSFT   316.92 (+1.13%)
META   300.76 (-0.06%)
GOOGL   133.83 (+1.06%)
AMZN   126.48 (+1.41%)
TSLA   252.78 (+2.54%)
NVDA   438.96 (+0.87%)
NIO   8.52 (-1.05%)
BABA   83.91 (-0.75%)
AMD   100.96 (+0.88%)
T   14.57 (-1.42%)
F   11.97 (-0.83%)
MU   67.88 (+0.07%)
CGC   0.69 (+0.95%)
GE   108.08 (+0.30%)
DIS   79.25 (-0.36%)
AMC   7.87 (+0.25%)
PFE   33.70 (-0.59%)
PYPL   57.75 (+0.79%)
NFLX   378.99 (+0.59%)
S&P 500   4,235.52 (+0.14%)
DOW   32,976.90 (-0.08%)
QQQ   357.04 (+0.60%)
AAPL   172.33 (-0.04%)
MSFT   316.92 (+1.13%)
META   300.76 (-0.06%)
GOOGL   133.83 (+1.06%)
AMZN   126.48 (+1.41%)
TSLA   252.78 (+2.54%)
NVDA   438.96 (+0.87%)
NIO   8.52 (-1.05%)
BABA   83.91 (-0.75%)
AMD   100.96 (+0.88%)
T   14.57 (-1.42%)
F   11.97 (-0.83%)
MU   67.88 (+0.07%)
CGC   0.69 (+0.95%)
GE   108.08 (+0.30%)
DIS   79.25 (-0.36%)
AMC   7.87 (+0.25%)
PFE   33.70 (-0.59%)
PYPL   57.75 (+0.79%)
NFLX   378.99 (+0.59%)
S&P 500   4,235.52 (+0.14%)
DOW   32,976.90 (-0.08%)
QQQ   357.04 (+0.60%)
AAPL   172.33 (-0.04%)
MSFT   316.92 (+1.13%)
META   300.76 (-0.06%)
GOOGL   133.83 (+1.06%)
AMZN   126.48 (+1.41%)
TSLA   252.78 (+2.54%)
NVDA   438.96 (+0.87%)
NIO   8.52 (-1.05%)
BABA   83.91 (-0.75%)
AMD   100.96 (+0.88%)
T   14.57 (-1.42%)
F   11.97 (-0.83%)
MU   67.88 (+0.07%)
CGC   0.69 (+0.95%)
GE   108.08 (+0.30%)
DIS   79.25 (-0.36%)
AMC   7.87 (+0.25%)
PFE   33.70 (-0.59%)
PYPL   57.75 (+0.79%)
NFLX   378.99 (+0.59%)
S&P 500   4,235.52 (+0.14%)
DOW   32,976.90 (-0.08%)
QQQ   357.04 (+0.60%)
AAPL   172.33 (-0.04%)
MSFT   316.92 (+1.13%)
META   300.76 (-0.06%)
GOOGL   133.83 (+1.06%)
AMZN   126.48 (+1.41%)
TSLA   252.78 (+2.54%)
NVDA   438.96 (+0.87%)
NIO   8.52 (-1.05%)
BABA   83.91 (-0.75%)
AMD   100.96 (+0.88%)
T   14.57 (-1.42%)
F   11.97 (-0.83%)
MU   67.88 (+0.07%)
CGC   0.69 (+0.95%)
GE   108.08 (+0.30%)
DIS   79.25 (-0.36%)
AMC   7.87 (+0.25%)
PFE   33.70 (-0.59%)
PYPL   57.75 (+0.79%)
NFLX   378.99 (+0.59%)
NYSE:EBS

Emergent BioSolutions (EBS) Stock Forecast, Price & News

$2.97
-0.02 (-0.67%)
(As of 09:45 AM ET)
Compare
Today's Range
$2.96
▼
$3.04
50-Day Range
$3.17
▼
$7.91
52-Week Range
$2.96
▼
$21.88
Volume
134,180 shs
Average Volume
1.80 million shs
Market Capitalization
$153.88 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$27.75
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability

Emergent BioSolutions MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
828.1% Upside
$27.75 Price Target
Short Interest
Bearish
18.95% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.40
Upright™ Environmental Score
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.24) to $2.10 Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.08 out of 5 stars

Medical Sector

538th out of 966 stocks

Pharmaceutical Preparations Industry

247th out of 450 stocks

See Top Rated MarketRank™ Stocks Here

EBS stock logo

About Emergent BioSolutions (NYSE:EBS) Stock

Emergent BioSolutions Inc., a life sciences company, focuses on the provision of preparedness and response solutions that address accidental, deliberate, and naturally occurring public health threats (PHTs) in the United States. Its products address PHTs, which include chemical, biological, radiological, nuclear, and explosives; emerging infectious diseases; travel health; public health crises; and acute, emergency, and community care. The company offers ACAM2000, a smallpox vaccine; Anthrasil to for inhalational anthrax; Botulism Antitoxin Heptavalent to treat botulinum disease; BioThrax, an anthrax vaccine; Ebanga, a monoclonal antibody to treat infection caused by Zaire ebolavirus; raxibacumab injection for the treatment of inhalational anthrax; reactive skin decontamination lotion kits; TEMBEXA for the treatment of human smallpox disease; Trobigard, an auto-injector atropine sulfate and obidoxime chloride auto-injector for the emergency treatment of known or suspected exposure to nerve agents; and vaccinia immune globulin intravenous that addresses complications from smallpox vaccine. It also provides NARCAN, a nasal spray for the emergency treatment of known or suspected opioid overdose; Vivotif, an oral vaccine for typhoid fever; and Vaxchora, a single-dose oral vaccine to treat cholera. In addition, the company is developing AV7909, an anthrax vaccine; CGRD-001, a pralidoxime chloride/atropine auto-injector; CHIKV VLP, a chikungunya virus VLP vaccine; EBS-LASV; EGRD-001, a diazepam auto-injector; SIAN, an antidote for the initial treatment of acute poisoning of cyanide; and UniFlu, a universal influenza vaccine. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.

EBS Price History

EBS Stock News Headlines

September 7, 2023 | finance.yahoo.com
Why Is Emergent Biosolutions (EBS) Down 22.6% Since Last Earnings Report?
August 30, 2023 | finance.yahoo.com
Emergent BioSolutions’ NARCAN® Nasal Spray Launches Over the Counter Making it Possible for Everyone to Help Save a Life from an Opioid Overdose Emergency
October 4, 2023 | Wall Street Fundamentals (Ad)
Would Buffett Approve of This Growth Strategy?
Warren Buffett's approach has been to find and invest in undervalued businesses with strong potential for growth. Taking this approach to heart and applying it to a Trillion Dollar industry has proved itself in a big way...achieving an incredible 400+% growth during a down market.
August 29, 2023 | msn.com
Benchmark cuts Emergent BioSolutions to hold as company restructures
August 29, 2023 | msn.com
Benchmark Downgrades Emergent Biosolutions (EBS)
August 23, 2023 | finance.yahoo.com
Moody's downgrades Emergent BioSolutions' credit rating, citing unpredictable revenue outlook
August 23, 2023 | msn.com
Emergent BioSolutions Is Clearly Risky, But The Reward Could Be Substantial
August 17, 2023 | finance.yahoo.com
Down -28.45% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS)
October 4, 2023 | Edge On The Street (Ad)
The Strategic Gold Play You Haven't Heard About
Experts recommend adding gold to your portfolio, but in what form? Some savvy investors are now rejecting coins and mining stocks in favor of a unique gold investment alternative. It holds explosive growth potential similar to a junior gold stock -- but with less risk exposure.
August 17, 2023 | finance.yahoo.com
Sonnet (SONN) Up as Ovarian Cancer Drug Enters Clinical Study
August 16, 2023 | finance.yahoo.com
Down -26.38% in 4 Weeks, Here's Why You Should You Buy the Dip in Emergent Biosolutions (EBS)
August 9, 2023 | finance.yahoo.com
Emergent (EBS) Q2 Earnings Miss Estimates, Revenues Beat
August 9, 2023 | markets.businessinsider.com
Emergent BioSolutions To Cut Operations, Plans 400 Job Cuts; COO Adam Havey To Leave
August 9, 2023 | finance.yahoo.com
Q2 2023 Emergent BioSolutions Inc Earnings Call
August 9, 2023 | finance.yahoo.com
Emergent BioSolutions (EBS) Q2 2023 Earnings Call Transcript
August 8, 2023 | finance.yahoo.com
Emergent Biosolutions (EBS) Reports Q2 Loss, Tops Revenue Estimates
August 8, 2023 | finance.yahoo.com
Emergent BioSolutions Reports Financial Results for Second Quarter 2023
August 8, 2023 | bizjournals.com
Emergent BioSolutions to lay off 400, reduce operations in Baltimore
August 8, 2023 | msn.com
Emergent BioSolutions to lay off about 400 employees
August 8, 2023 | finance.yahoo.com
Emergent BioSolutions to lay off 400 as its scales back its contract manufacturing business
August 8, 2023 | finance.yahoo.com
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
August 8, 2023 | finance.yahoo.com
UPDATE 1-Emergent BioSolutions to lay off about 400 employees
August 1, 2023 | finance.yahoo.com
Gaithersburg's Emergent BioSolutions lands large federal contract to boost development of Ebola drug
July 31, 2023 | markets.businessinsider.com
Why Emergent Biosolutions Stock Is Surging After The Close
July 31, 2023 | finance.yahoo.com
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
July 25, 2023 | finance.yahoo.com
Emergent BioSolutions to Release Second Quarter 2023 Financial Results and Conduct Conference Call on August 8, 2023
July 21, 2023 | msn.com
Emergent Bio (NYSE:EBS) Soars on Approval for Anthrax Vaccine
See More Headlines
Receive EBS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Emergent BioSolutions and its competitors with MarketBeat's FREE daily newsletter.

EBS Company Calendar

Last Earnings
8/08/2023
Today
10/04/2023
Next Earnings (Estimated)
11/14/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NYSE
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NYSE:EBS
CUSIP
29089Q10
CIK
1367644
Web
www.emergentbiosolutions.com
Phone
(240) 631-3200
Fax
301-795-1899
Employees
2,500
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$27.75
High Stock Price Forecast
$55.00
Low Stock Price Forecast
$9.00
Forecasted Upside/Downside
+828.1%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
3 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($12.08)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-223,800,000.00
Net Margins
-56.63%
Pretax Margin
-50.89%
Return on Equity
-23.29%
Return on Assets
-10.38%

Debt

Debt-to-Equity Ratio
0.47
Current Ratio
1.12
Quick Ratio
0.61

Sales & Book Value

Annual Sales
$1.12 billion
Price / Sales
0.14
Cash Flow
$0.67 per share
Price / Cash Flow
4.44
Book Value
$27.72 per share
Price / Book
0.11

Miscellaneous

Outstanding Shares
51,810,000
Free Float
46,056,000
Market Cap
$154.91 million
Optionable
Optionable
Beta
0.94
5G Stocks: The Path Forward is Profitable Cover
5G Stocks: The Path Forward is Profitable

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Key Executives

  • Mr. Richard S. Lindahl M.B.A.Mr. Richard S. Lindahl M.B.A. (Age 59)
    Exec. VP, CFO & Treasurer
    Comp: $799.38k
  • Mr. Adam R. Havey (Age 52)
    Exec. VP & COO
    Comp: $755.44k
  • Ms. Jennifer L. Fox
    Exec. VP of External Affairs, Gen. Counsel & Corp. Sec.
  • Mr. Haywood Miller
    Interim Chief Exec. Officer
  • Mr. Robert G. Burrows
    VP of Investor Relations
  • Ms. Coleen Glessner
    Exec. VP of Global Quality and Ethics & Compliance
  • Michelle Pepin
    Sr. VP & Chief Human Resource Officer
  • Ms. Stephanie Duatschek
    Sr. VP, Chief Strategy & Transformation Officer
  • Dr. Kelly Lyn Warfield
    Sr. VP of Science & Devel.
  • Mr. Paul A. Williams
    Sr. VP of Products Bus.

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













EBS Stock - Frequently Asked Questions

Should I buy or sell Emergent BioSolutions stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Emergent BioSolutions in the last twelve months. There are currently 1 sell rating, 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" EBS shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in EBS, but not buy additional shares or sell existing shares.
View EBS analyst ratings or view top-rated stocks.

What is Emergent BioSolutions' stock price forecast for 2023?

3 analysts have issued 12 month price targets for Emergent BioSolutions' shares. Their EBS share price forecasts range from $9.00 to $55.00. On average, they anticipate the company's stock price to reach $27.75 in the next twelve months. This suggests a possible upside of 828.1% from the stock's current price.
View analysts price targets for EBS or view top-rated stocks among Wall Street analysts.

How have EBS shares performed in 2023?

Emergent BioSolutions' stock was trading at $11.81 on January 1st, 2023. Since then, EBS stock has decreased by 74.7% and is now trading at $2.99.
View the best growth stocks for 2023 here.

Are investors shorting Emergent BioSolutions?

Emergent BioSolutions saw a increase in short interest in September. As of September 15th, there was short interest totaling 9,460,000 shares, an increase of 12.8% from the August 31st total of 8,390,000 shares. Based on an average daily trading volume, of 2,340,000 shares, the short-interest ratio is presently 4.0 days. Approximately 19.0% of the shares of the stock are sold short.
View Emergent BioSolutions' Short Interest.

When is Emergent BioSolutions' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 14th 2023.
View our EBS earnings forecast.

How were Emergent BioSolutions' earnings last quarter?

Emergent BioSolutions Inc. (NYSE:EBS) announced its quarterly earnings data on Tuesday, August, 8th. The biopharmaceutical company reported ($1.06) EPS for the quarter, missing analysts' consensus estimates of ($0.98) by $0.08. The biopharmaceutical company had revenue of $337.90 million for the quarter, compared to the consensus estimate of $216.17 million. Emergent BioSolutions had a negative trailing twelve-month return on equity of 23.29% and a negative net margin of 56.63%. The business's revenue was up 39.2% on a year-over-year basis. During the same period last year, the business posted ($0.86) EPS.

What ETF holds Emergent BioSolutions' stock ?

ETFMG Treatments Testing and Advancements ETF holds 14,243 shares of EBS stock, representing 0.70% of its portfolio.

What guidance has Emergent BioSolutions issued on next quarter's earnings?

Emergent BioSolutions updated its third quarter 2023 earnings guidance on Tuesday, August, 8th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $210.00 million-$250.00 million, compared to the consensus revenue estimate of $326.87 million.

What is Bob Kramer's approval rating as Emergent BioSolutions' CEO?

38 employees have rated Emergent BioSolutions Chief Executive Officer Bob Kramer on Glassdoor.com. Bob Kramer has an approval rating of 74% among the company's employees.

What other stocks do shareholders of Emergent BioSolutions own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Emergent BioSolutions investors own include NVIDIA (NVDA), Salesforce (CRM), Novavax (NVAX), Advanced Micro Devices (AMD), Block (SQ), Netflix (NFLX), Gilead Sciences (GILD), PayPal (PYPL), Johnson & Johnson (JNJ) and AbbVie (ABBV).

What is Emergent BioSolutions' stock symbol?

Emergent BioSolutions trades on the New York Stock Exchange (NYSE) under the ticker symbol "EBS."

How do I buy shares of Emergent BioSolutions?

Shares of EBS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Emergent BioSolutions' stock price today?

One share of EBS stock can currently be purchased for approximately $2.99.

How much money does Emergent BioSolutions make?

Emergent BioSolutions (NYSE:EBS) has a market capitalization of $154.91 million and generates $1.12 billion in revenue each year. The biopharmaceutical company earns $-223,800,000.00 in net income (profit) each year or ($12.08) on an earnings per share basis.

How many employees does Emergent BioSolutions have?

The company employs 2,500 workers across the globe.

How can I contact Emergent BioSolutions?

Emergent BioSolutions' mailing address is 400 PROFESSIONAL DR SUITE 400, GAITHERSBURG MD, 20879. The official website for the company is www.emergentbiosolutions.com. The biopharmaceutical company can be reached via phone at (240) 631-3200, via email at burrowsr@ebsi.com, or via fax at 301-795-1899.

This page (NYSE:EBS) was last updated on 10/4/2023 by MarketBeat.com Staff

My Account -